MicroRNA-31 inhibits cisplatin-induced apoptosis in non-small cell lung cancer cells by regulating the drug transporter ABCB9

Cancer Letters

Volumn 343, Issue 2, 2014, Pages 249-257

  Dong, Zhuo ^a   Zhong, Zhiwei ^a   Yang, Lihua ^a   Wang, Shaomin ^a   Gong, Zhaohui ^a  

^a NINGBO UNIVERSITY   (China)

Author keywords

ABCB9; Apoptosis; Cisplatin resistance; MiR 31; Non small cell lung cancer

Indexed keywords

CISPLATIN; MICRORNA 31;

3' UNTRANSLATED REGION; ABCB9 GENE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER RESISTANCE; CONTROLLED STUDY; DRUG SENSITIVITY; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; UPREGULATION;

ABCB9; APOPTOSIS; CISPLATIN RESISTANCE; MIR-31; NON-SMALL CELL LUNG CANCER;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ATP-BINDING CASSETTE TRANSPORTERS; CARCINOMA, NON-SMALL-CELL LUNG; CELL SURVIVAL; CISPLATIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MICRORNAS; REAL-TIME POLYMERASE CHAIN REACTION; UP-REGULATION;

EID: 84891829677     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.09.034     Document Type: Article

References (39)

1. Eaton K.D., Martins R.G. Maintenance chemotherapy in non-small cell lung cancer. J. Natl. Compr. Canc. Netw. 2010, 8:815-821.
2. Chang A. Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. Lung Cancer 2011, 71:3-10.
3. Szakacs G., Paterson J.K., Ludwig J.A., Booth-Genthe C., Gottesman M.M. Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 2006, 5:219-234.
4. Galluzzi L., Senovilla L., Vitale I., Michels J., Martins I., Kepp O., Castedo M., Kroemer G. Molecular mechanisms of cisplatin resistance. Oncogene 2012, 31:1869-1883.
5. Kuo M.T., Fu S., Savaraj N., Chen H.H. Role of the human high-affinity copper transporter in copper homeostasis regulation and cisplatin sensitivity in cancer chemotherapy. Cancer Res. 2012, 72:4616-4621.
6. Shen D.W., Pouliot L.M., Hall M.D., Gottesman M.M. Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol. Rev. 2012, 64:706-721.
7. Gillet J.P., Gottesman M.M. Advances in the molecular detection of ABC transporters involved in multidrug resistance in cancer. Curr. Pharm. Biotechnol. 2011, 12:686-692.
8. Demirel O., Bangert I., Tampe R., Abele R. Tuning the cellular trafficking of the lysosomal peptide transporter TAPL by its N-terminal domain. Traffic 2010, 11:383-393.
9. Hlavata I., Mohelnikova-Duchonova B., Vaclavikova R., Liska V., Pitule P., Novak P., Bruha J., Vycital O., Holubec L., Treska V., Vodicka P., Soucek P. The role of ABC transporters in progression and clinical outcome of colorectal cancer. Mutagenesis 2012, 27:187-196.
10. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
11. Boeri M., Pastorino U., Sozzi G. Role of microRNAs in lung cancer: microRNA signatures in cancer prognosis. Cancer J. 2012, 18:268-274.
12. Di Lisio L., Martinez N., Montes-Moreno S., Piris-Villaespesa M., Sanchez-Beato M., Piris M.A. The role of miRNAs in the pathogenesis and diagnosis of B-cell lymphomas. Blood 2012, 120:1782-1790.
13. Kong Y.W., Ferland-McCollough D., Jackson T.J., Bushell M. MicroRNAs in cancer management. Lancet Oncol. 2012, 13:e249-258.
14. Melo S.A., Kalluri R. Molecular pathways: microRNAs as cancer therapeutics. Clin. Cancer Res. 2012, 18:4234-4239.
15. Blower P.E., Chung J.H., Verducci J.S., Lin S., Park J.K., Dai Z., Liu C.G., Schmittgen T.D., Reinhold W.C., Croce C.M., Weinstein J.N., Sadee W. MicroRNAs modulate the chemosensitivity of tumor cells. Mol. Cancer Ther. 2008, 7:1-9.
16. Du L., Subauste M.C., DeSevo C., Zhao Z., Baker M., Borkowski R., Schageman J.J., Greer R., Yang C.R., Suraokar M., Wistuba, Gazdar A.F., Minna J.D., Pertsemlidis A. miR-337-3p and its targets STAT3 and RAP1A modulate taxane sensitivity in non-small cell lung cancers. PLoS One 2012, 7:e39167.
17. Galluzzi L., Morselli E., Vitale I., Kepp O., Senovilla L., Criollo A., Servant N., Paccard C., Hupe P., Robert T., Ripoche H., Lazar V., Harel-Bellan A., Dessen P., Barillot E., Kroemer G. MiR-181a and miR-630 regulate cisplatin-induced cancer cell death. Cancer Res. 2010, 70:1793-1803.
18. Garofalo M., Romano G., Di Leva G., Nuovo G., Jeon Y.J., Ngankeu A., Sun J., Lovat F., Alder H., Condorelli G., Engelman J.A., Ono M., Rho J.K., Cascione L., Volinia S., Nephew K.P., Croce C.M. EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat. Med. 2012, 18:74-82.
19. Cottonham C.L., Kaneko S., Xu L. MiR-21 and miR-31 converge on TIAM1 to regulate migration and invasion of colon carcinoma cells. J. Biol. Chem. 2010, 285:35293-35302.
20. Liu X., Sempere L.F., Ouyang H., Memoli V.A., Andrew A.S., Luo Y., Demidenko E., Korc M., Shi W., Preis M., Dragnev K.H., Li H., Direnzo J., Bak M., Freemantle S.J., Kauppinen S., Dmitrovsky E. MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. J. Clin. Invest. 2010, 120:1298-1309.
21. Valastyan S., Reinhardt F., Benaich N., Calogrias D., Szasz A.M., Wang Z.C., Brock J.E., Richardson A.L., Weinberg R.A. A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell 2009, 137:1032-1046.
22. Yamagishi M., Nakano K., Miyake A., Yamochi T., Kagami Y., Tsutsumi A., Matsuda Y., Sato-Otsubo A., Muto S., Utsunomiya A., Yamaguchi K., Uchimaru K., Ogawa S., Watanabe T. Polycomb-mediated loss of miR-31 activates NIK-dependent NF-kappaB pathway in adult T cell leukemia and other cancers. Cancer Cell 2012, 21:121-135.
23. Bhatnagar N., Li X., Padi S.K., Zhang Q., Tang M.S., Guo B. Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells. Cell Death Dis. 2010, 1:e105.
24. Wang C.J., Stratmann J., Zhou Z.G., Sun X.F. Suppression of microRNA-31 increases sensitivity to 5-FU at an early stage, and affects cell migration and invasion in HCT-116 colon cancer cells. BMC Cancer 2010, 10:616.
25. Zhong Z., Dong Z., Yang L., Chen X., Gong Z. MicroRNA-31-5p modulates cell cycle by targeting human mutL homolog 1 in human cancer cells. Tumour Biol. 2013, 34:1959-1965.
26. Pan Y.Z., Morris M.E., Yu A.M. MicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cells. Mol. Pharmacol. 2009, 75:1374-1379.
27. To K.K., Zhan Z., Litman T., Bates S.E. Regulation of ABCG2 expression at the 3' untranslated region of its mRNA through modulation of transcript stability and protein translation by a putative microRNA in the S1 colon cancer cell line. Mol. Cell. Biol. 2008, 28:5147-5161.
28. Zhu H., Wu H., Liu X., Evans B.R., Medina D.J., Liu C.G., Yang J.M. Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Biochem. Pharmacol. 2008, 76:582-588.
29. Rosell R., Cuello M., Cecere F., Santarpia M., Reguart N., Felip E., Taron M. Treatment of non-small-cell lung cancer and pharmacogenomics: where we are and where we are going. Curr. Opin. Oncol. 2006, 18:135-143.
30. Giovannetti E., Toffalorio F., De Pas T., Peters G.J. Pharmacogenetics of conventional chemotherapy in non-small-cell lung cancer: a changing landscape?. Pharmacogenomics 2012, 13:1073-1086.
31. Loriot Y., Mordant P., Deutsch E., Olaussen K.A., Soria J.C. Are RAS mutations predictive markers of resistance to standard chemotherapy?. Nat. Rev. Clin. Oncol. 2009, 6:528-534.
32. Chen Z.S., Tiwari A.K. Multidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic diseases. FEBS J. 2011, 278:3226-3245.
33. Glavinas H., Krajcsi P., Cserepes J., Sarkadi B. The role of ABC transporters in drug resistance, metabolism and toxicity. Curr. Drug. Deliv. 2004, 1:27-42.
34. Zhang F., Zhang W., Liu L., Fisher C.L., Hui D., Childs S., Dorovini-Zis K., Ling V. Characterization of ABCB9, an ATP binding cassette protein associated with lysosomes. J. Biol. Chem. 2000, 275:23287-23294.
35. Ohashi-Kobayashi A., Ohashi K., Du W.B., Omote H., Nakamoto R., Al-Shawi M., Maeda M. Examination of drug resistance activity of human TAP-like (ABCB9) expressed in yeast. Biochem. Biophys. Res. Commun. 2006, 343:597-601.
36. Du L., Pertsemlidis A. MicroRNA regulation of cell viability and drug sensitivity in lung cancer. Expert Opin. Biol. Ther. 2012, 12:1221-1239.
37. Lin P.Y., Yu S.L., Yang P.C. MicroRNA in lung cancer. Brit. J. Cancer 2010, 103:1144-1148.
38. Imanaka Y., Tsuchiya S., Sato F., Shimada Y., Shimizu K., Tsujimoto G. MicroRNA-141 confers resistance to cisplatin-induced apoptosis by targeting YAP1 in human esophageal squamous cell carcinoma. J. Hum. Genet. 2011, 56:270-276.
39. Kim E.H., Lee H.J., Lee D.H., Bae S., Soh J.W., Jeoung D., Kim J., Cho C.K., Lee Y.J., Lee Y.S. Inhibition of heat shock protein 27-mediated resistance to DNA damaging agents by a novel PKCδ-V5 heptapeptide. Cancer Res. 2007, 67:6333-6339.